Regulatory T Cell-Enhancing Therapies to Treat Atherosclerosis
Experimental studies have provided strong evidence that chronic inflammation triggered by the sub-endothelial accumulation of cholesterol-rich lipoproteins in arteries is essential in the initiation and progression of atherosclerosis. Recent clinical trials highlighting the efficacy of anti-inflamma...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/10/4/723 |
| _version_ | 1797540169939681280 |
|---|---|
| author | Hafid Ait-Oufella Jean-Rémi Lavillegrand Alain Tedgui |
| author_facet | Hafid Ait-Oufella Jean-Rémi Lavillegrand Alain Tedgui |
| author_sort | Hafid Ait-Oufella |
| collection | DOAJ |
| description | Experimental studies have provided strong evidence that chronic inflammation triggered by the sub-endothelial accumulation of cholesterol-rich lipoproteins in arteries is essential in the initiation and progression of atherosclerosis. Recent clinical trials highlighting the efficacy of anti-inflammatory therapies in coronary patients have confirmed that this is also true in humans Monocytes/macrophages are central cells in the atherosclerotic process, but adaptive immunity, through B and T lymphocytes, as well as dendritic cells, also modulates the progression of the disease. Analysis of the role of different T cell subpopulations in murine models of atherosclerosis identified effector Th1 cells as proatherogenic, whereas regulatory T cells (Tregs) have been shown to protect against atherosclerosis. For these reasons, better understanding of how Tregs influence the atherosclerotic process is believed to provide novel Treg-targeted therapies to combat atherosclerosis. This review article summarizes current knowledge about the role of Tregs in atherosclerosis and discusses ways to enhance their function as novel immunomodulatory therapeutic approaches against cardiovascular disease. |
| first_indexed | 2024-03-10T12:57:13Z |
| format | Article |
| id | doaj.art-8e38fbc7602544b586c731d8b3ad24e7 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T12:57:13Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-8e38fbc7602544b586c731d8b3ad24e72023-11-21T11:51:03ZengMDPI AGCells2073-44092021-03-0110472310.3390/cells10040723Regulatory T Cell-Enhancing Therapies to Treat AtherosclerosisHafid Ait-Oufella0Jean-Rémi Lavillegrand1Alain Tedgui2Paris Cardiovascular Research Center—PARCC, Université de Paris, INSERM UMR-S 970, 75012 Paris, FranceParis Cardiovascular Research Center—PARCC, Université de Paris, INSERM UMR-S 970, 75012 Paris, FranceParis Cardiovascular Research Center—PARCC, Université de Paris, INSERM UMR-S 970, 75012 Paris, FranceExperimental studies have provided strong evidence that chronic inflammation triggered by the sub-endothelial accumulation of cholesterol-rich lipoproteins in arteries is essential in the initiation and progression of atherosclerosis. Recent clinical trials highlighting the efficacy of anti-inflammatory therapies in coronary patients have confirmed that this is also true in humans Monocytes/macrophages are central cells in the atherosclerotic process, but adaptive immunity, through B and T lymphocytes, as well as dendritic cells, also modulates the progression of the disease. Analysis of the role of different T cell subpopulations in murine models of atherosclerosis identified effector Th1 cells as proatherogenic, whereas regulatory T cells (Tregs) have been shown to protect against atherosclerosis. For these reasons, better understanding of how Tregs influence the atherosclerotic process is believed to provide novel Treg-targeted therapies to combat atherosclerosis. This review article summarizes current knowledge about the role of Tregs in atherosclerosis and discusses ways to enhance their function as novel immunomodulatory therapeutic approaches against cardiovascular disease.https://www.mdpi.com/2073-4409/10/4/723atherosclerosisimmunitycytokinesT lymphocytesregulatory T cells |
| spellingShingle | Hafid Ait-Oufella Jean-Rémi Lavillegrand Alain Tedgui Regulatory T Cell-Enhancing Therapies to Treat Atherosclerosis Cells atherosclerosis immunity cytokines T lymphocytes regulatory T cells |
| title | Regulatory T Cell-Enhancing Therapies to Treat Atherosclerosis |
| title_full | Regulatory T Cell-Enhancing Therapies to Treat Atherosclerosis |
| title_fullStr | Regulatory T Cell-Enhancing Therapies to Treat Atherosclerosis |
| title_full_unstemmed | Regulatory T Cell-Enhancing Therapies to Treat Atherosclerosis |
| title_short | Regulatory T Cell-Enhancing Therapies to Treat Atherosclerosis |
| title_sort | regulatory t cell enhancing therapies to treat atherosclerosis |
| topic | atherosclerosis immunity cytokines T lymphocytes regulatory T cells |
| url | https://www.mdpi.com/2073-4409/10/4/723 |
| work_keys_str_mv | AT hafidaitoufella regulatorytcellenhancingtherapiestotreatatherosclerosis AT jeanremilavillegrand regulatorytcellenhancingtherapiestotreatatherosclerosis AT alaintedgui regulatorytcellenhancingtherapiestotreatatherosclerosis |